Physician profile

Catherine Kubiak

Allergy & Immunology · Largo, FL

NPI 1770801953

$692.00

in general payments reported to CMS, 2019-2025

7 companies · $134 in 2025

The $134 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).

See the full distribution for Allergy & Immunology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$284.28
Education$23.32

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Takeda Pharmaceuticals U.S.A., INC. $157.01 2021-2022
Adma Biomanufacturing LLC $150.00 2024
Genentech USA, INC. $149.99 2019
Regeneron Healthcare Solutions, INC. $134.28 2025 Dupixent
Teva Pharmaceuticals USA, INC. $42.45 2019
Pfizer INC. $34.95 2019
Astrazeneca Pharmaceuticals LP $23.32 2024 Airsupra

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Catherine Kubiak

$692.00

in general payments reported 2019-2025

Years
2019-2025
Top company
Takeda Pharmaceuticals U.S.A., INC.
Context
The $134 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).

https://glasscript.com/doctor/1372716/catherine-kubiak

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.